{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-09-04T00:25:52.337952+00:00","company":{"ticker":"SCNI","cik":1611747,"company_name":"Scinai Immunotherapeutics Ltd."},"pagination":{"limit":100,"returned":3,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","counterparties":{"contract_counterparty":[{"display_name":"Max-Planck-Innovation GmbH and the University Medical Center Gottingen","detail":"license","count":1,"first_seen":"2023-06-08T23:59:59+00:00","last_seen":"2023-06-08T23:59:59+00:00","evidence_fact_ids":[141763]}]},"facts":[{"fact_type":"material_agreement","fact_key":"12d37fb68764be19629bc8b33fe8cb9fe26beb31","cik":1611747,"ticker":"SCNI","company_name":"Scinai Immunotherapeutics Ltd.","filed_at":"2023-06-08T23:59:59+00:00","payload":{"action":"entry","agreement_name":"License Agreement","agreement_type":"license","counterparty":"Max-Planck-Innovation GmbH and the University Medical Center Gottingen","effective_date":"2023-06-04","item_codes_triggered":["1.01"],"value_text":null},"claim":"Scinai Immunotherapeutics Ltd. entered into License Agreement with Max-Planck-Innovation GmbH and the University Medical Center Gottingen (effective 2023-06-04).","evidence_excerpt":"On June 4, 2023, BiondVax Pharmaceuticals Ltd. (the “Company” or “BiondVax”) entered into a License Agreement (the “License Agreement”) with the Max-Planck-Innovation GmbH, the technology transfer agency of the Max Planck Society in Germany(“MI”) and the University Medical Center Gottingen (“UMG”) to develop and commercialize VHH antibodies (NanoAbs) targeting Interleukin-17 (IL-17) (the “Target”) as treatments for all potential indications.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-23-047493","anchor_url":"https://secwatch.observer/filing/0001213900-23-047493#claim-12d37fb68764be19629bc8b33fe8cb9fe26beb31","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1611747/000121390023047493/0001213900-23-047493-index.htm"},{"fact_type":"executive_change","fact_key":"e75ac5153c","cik":1611747,"ticker":"SCNI","company_name":"Scinai Immunotherapeutics Ltd.","filed_at":"2023-05-11T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2023-05-12","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"George H. Lowell resigned as Director at Scinai Immunotherapeutics Ltd..","evidence_excerpt":"On May 10, 2023, Mr. George H. Lowell submitted to the board of directors (the “Board”) of BiondVax Pharmaceuticals Ltd. (the “Company”) his resignation from his position as a member of the Board, effective May 12, 2023.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-23-038612","anchor_url":"https://secwatch.observer/filing/0001213900-23-038612#claim-e75ac5153c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1611747/000121390023038612/0001213900-23-038612-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"43161ae496dbac8f90f9f0b60d7de049d60d9f58","cik":1611747,"ticker":"SCNI","company_name":"Scinai Immunotherapeutics Ltd.","filed_at":"2023-05-04T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"deficient","cure_deadline":null,"deficiency_type":"stockholders_equity","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2023-05-01","notice_type":"deficiency_notice","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":["5550(b)(1)"],"rules_cited_in_text":true},"claim":"Scinai Immunotherapeutics Ltd. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).","evidence_excerpt":"May 1, 2023, BiondVax\nPharmaceuticals Ltd. (the “ Company ”) received a deficiency letter from the staff of the Listing Qualifications Department\n(the “ Staff ”) of the Nasdaq Stock Market (“ Nasdaq ”) notifying the Company that it is not in compliance\nwith the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1)\nrequires companies listed on the Nasdaq Capital Market to maintain stockholders’ equity of at least $2,500,000 (the “ Stockholders’\nEquity Requirement ”). The Company’s Annual Report on Form 10-K for the year ended","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-23-036435","anchor_url":"https://secwatch.observer/filing/0001213900-23-036435#claim-43161ae496dbac8f90f9f0b60d7de049d60d9f58","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1611747/000121390023036435/0001213900-23-036435-index.htm"}]}